この成分は何ですか?

이 원료는 다음의 구조를 갖는 탄화수소이다.

成分一覧

成分辞典

HEXENE

1-hexene is an alkene that is hexane carrying a double bond at position 1.

定義

1-hexene is an alkene that is hexane carrying a double bond at position 1.

出典: PubChem

米国FDA 物質登録 · UNII B38ZZ8C206 · 登録名 1-HEXENE · 単一の化学物質

出典: 米国FDA 物質識別番号（UNII）

化粧品での役割

他の成分を溶かす基剤SOLVENT

安全性・規制情報

韓国の有害物質GHS分類なし · 既存化学物質

出典: 韓国有害物質GHS情報（環境公団）

Other restriction: ban substances that deplete the ozone layer

出典: EU CosIng 成分リスト

詳しい資料 — 表示名・識別番号・物性・試験記録・文献

別名・識別情報

HEXENEINCI헥센韓国の表示名（食薬処標準名）1-Hexene別名

CAS No.化学物質登録番号: 592-41-6
EC No.EU化学物質目録番号: 209-753-1
DTXSID米国EPA化学物質番号: DTXSID4025402
DTXCID米国EPA化合物番号: DTXCID105402

IUPAC: Hex-1-ene
分子式: C6H12
分子量: 84.162 g/mol

測定された物性

性状: 1-hexene appears as a clear colorless liquid with a petroleum like odor. Flash point -9 °F. Less dense than water and insoluble in water. Vapors heavier than air. Used as a solvent, paint thinner, and chemical reaction medium. · CBI, Liquid
沸点: 146.3 °F at 760 mmHg (USCG, 1999) · 63.4 °C @ 760 mm Hg
融点: -219.6 °F (USCG, 1999) · -139.7 °C
溶解性: Very sol in ethanol, ethyl ether, benzene, and petroleum ether · In water, 50 mg/l at 25 °C
密度: 0.673 at 68 °F (USCG, 1999) - Less dense than water, will float · 0.6731 @ 20 °C/4 °C
粘度: 0.39 sq mm/s
融点・凝固点: -140 ℃
初留点および沸点範囲: 63 ℃
引火点: -26 ℃(c.c.)
燃焼・爆発範囲の上限/下限: 6.9 / 1.2 %
蒸気圧: 18.7 ㎪ (20℃)
溶解度: 0.005 ( 20℃)
蒸気密度: 2.9
比重: 0.7
n-オクタノール/水分配係数（Kow）: 3.39
自然発火温度: 253 ℃
分子量: 84.2

物質そのものを測定した値です。安全保健公団（KOSHA）の資料はSDS作成・確認の参考用で、原料商品の規格ではありません。

出典: PubChem · 韓国安全保健公団 SDS

製品が実際に使っている用途

米国EPAにこの成分を届け出た製品17件の用途です。化粧品以外の製品も含まれるため、上の数行がこの成分の主な使い道といえます。

Monomers4
Intermediate3
Fuel2
Processing aids not otherwise specified2
Lubricating agent2
Viscosity modifier2
Solvent1
Surfactant (surface active agent)1

出典: 米国EPA CompTox

刺激・感作試験の記録

皮膚試験18件・眼試験7件の記録があります。

刺激が強いと分類3件中程度と分類3件低いと分類33件

試験ごとに結論が分かれています（最も多い結論の割合 8%）。この成分が刺激性だとは言い切れないということです。原料そのものを試験した記録で、完成品に含まれる濃度での刺激性とは異なります。

試験25件をすべて見る

Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to EPA OTS 798.4470 (Acute Dermal Irritation) according to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) equivalent or similar to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · equivalent or similar to OECD Guideline 406 (Skin Sensitisation)
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation)
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: Federal Hazardous Substances Labelling Act (FHSLA) according to
Not classified
Skin Irritation · Screening
Not classified
Skin Sensitization · Screening
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: Federal Hazardous Substances Labeling Act (FHSLA) according to
Severe Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to
Moderate or Mild Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to
Category 6.3B (Category 3)
Skin Irritation · Read Across
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: U.S. EPA FIFRA (Pesticide Assessment Guidelines Subdivision F/TSCA (798.4470) according to OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: Magnusson and Kligman
Severe Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to EPA OTS 798.4470 (Acute Dermal Irritation) according to
Moderate or Mild Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) equivalent or similar to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: Federal Hazardous Substance Labelling Act (FHSLA) according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) equivalent or similar to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: Federal Hazardous Substances Labeling Act (FHSLA) according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: Federal Hazardous Substances Labelling Act according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to
Not classified
Eye Irritation · Screening
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: Federal Register 28 (110), 6.6.1963. paragraph 191.12 Test for eye irritants. according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to